Skip to main content
. Author manuscript; available in PMC: 2014 Sep 28.
Published in final edited form as: Cancer Lett. 2013 Apr 2;338(2):229–238. doi: 10.1016/j.canlet.2013.03.032

Fig. 2. BKM120 combined with TRAIL synergistically decreases the survival (A) and induces caspase-dependent apoptosis (B–D) of human NSCLC cells.

Fig. 2

A, The indicated cell lines were seeded in 96-well plates and treated the next day with different concentrations of TRAIL alone, BKM120 alone and their respective combinations as indicated. After 24 h, cell numbers were estimated using the SRB assay. Columns, means of four replicate determinations; bars, ± SD. B and C, The given cell lines were treated with 2 µM BKM120, 20 ng/ml TRAIL or their combination for 24 h and then harvested for detection of annexin V-positive cells with flow cytometry (B) and caspase cleavage with Western blotting (C). Columns, means of duplicate determinations; bars, ± SD. Pro-casp, pro-caspase; CF, cleaved form. D, H1299 cells were pre-treated with 20 µM Z-VAD-fmk for 30 min and then co-treated with DMSO, 2 µM BKM120, 20 ng/ml TRAIL or the combination of BKM120 and TRAIL. After 16 h, the cells were assayed for histone-associated DNA fragments with a cell death ELISA kit. Columns, means of triplicate determinations; bars, ± SD. Comb, combination.